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A B S T R A C T
Caspofungin, in association with other antifungal
drugs, was administered as rescue therapy in two
cases of documented and one case of possible
invasive fungal infection in children with acute
leukaemia or undergoing allogeneic bone marrow
transplant. The combined therapy was well-toler-
ated and seemed to be effective in all three
patients. A combination antifungal therapy inclu-
ding caspofungin could represent an effective
therapy for children with invasive mycoses
refractory to single-agent antifungal therapy.
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Fungal pneumonia represents a severe complica-
tion after chemotherapy for acute leukaemia or
haematopoietic stem cell transplant [1]. Standard
treatment with amphotericin B deoxycholate has a
14–83% overall response rate [2]. Caspofungin is
a new echinocandin with broad-spectrum activ-
ity. Its efficacy in association with other drugs for
the treatment of severe refractory mycoses in
adults has been reported previously [3–6], but
there are no data on the efficacy of such combi-
nation therapies in children. Available data on
paediatric uses are preliminary with regard to
pharmacokinetics and safety [7]. This report
describes the use of caspofungin in combination
with other antifungal drugs for the treatment of
refractory fungal pneumonia in three children.
Since no data regarding caspofungin paediatric
dosages were available at the time of these
observations, it was decided to administer caspo-
fungin according to each child’s body surface
area. The dose was calculated by dividing the
adult dose—70 mg ⁄day (loading) and 50 mg ⁄day
(maintenance)—by 1.73 m2 (a typical adult’s body
surface area), thereby suggesting doses of
40 mg ⁄m2 ⁄day (loading) and 30 mg ⁄m2 ⁄day
(maintenance).
The first patient, a 14-year-old neutropenic
(granulocyte count < 1000 ⁄ cm2) male with relap-
sing acute lymphoblastic leukaemia, developed
clinical signs of pulmonary disease associated
with a CT scan showing a nodule with a halo sign.
Initial therapy was with amphotericin B deoxych-
olate 1 mg ⁄kg ⁄day, changed subsequently to
liposomal amphotericin B 5 mg ⁄ kg ⁄day because
of renal toxicity. After therapy for 2 weeks, the
patient presented with haemoptysis, and a CT
scan showed two cavitating pulmonary lesions.
Surgical management of the pulmonary lesions
was required, but was delayed because of the
patient’s poor clinical condition. In an attempt to
obtain a rapid reduction in pulmonary inflamma-
tion and accelerate the possibility of surgical
intervention, caspofungin was combined with
liposomal amphotericin B. The clinical and radio-
logical features improved rapidly, and surgery
was performed after therapy with the combina-
tion for 10 days. Histological examination of the
pulmonary lesions showed the presence of fila-
mentous fungi infiltrating the pulmonary tissue,
but no growth was obtained on culture. Multiple
tests for serum galactomannan antigen (s-GM-a)
throughout the clinical course were always neg-
ative. In total, the patient received the combina-
tion therapy for 60 days with no sign of toxicity.
The second patient was a 12-year-old male,
suffering from Fanconi’s anaemia, who had
received allogeneic haematopoietic stem cell
transplant from a matched unrelated donor. After
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85 days, in the absence of neutropenia, but while
receiving cyclosporin and high-dose corticoster-
oids for severe chronic extensive graft-versus-host
disease, the patient developed fever and clinical
signs of pneumonia. A chest CT scan showed the
presence of multiple pulmonary lesions, one of
which had a halo sign. Liposomal amphotericin B
5 mg ⁄ kg ⁄day was administered, and the patient’s
clinical condition improved. However, after
27 days, the respiratory symptoms and chest CT
scan appearance deteriorated, and caspofungin
was added to liposomal amphotericin B. This
therapy was followed by clinical and radiological
improvement. After 26 days of this combination,
cyclosporin was substituted with tacrolimus
because of increased transaminase levels
(aspartate aminotransferase 66 IU ⁄mL, alanine
aminotransferase 276 IU ⁄mL), which resulted in
a prompt reduction of liver enzymes to normal
values. Since caspofungin could have modified
the pharmacokinetics of tacrolimus, plasma levels
were monitored twice a week and maintained
within the therapeutic range. Multiple tests for
the presence of s-GM-a were always negative. The
patient received combination therapy for a total of
45 days.
The third patient was an 11-year-old male
receiving a T-depleted haplo-identical allogeneic
haematopoietic stem cell transplant. Liposomal
amphotericin B 3 mg ⁄ kg ⁄day was administered
because of respiratory symptoms associated with
pulmonary lesions with a halo sign on CT scan
and a positive s-GM-a test during pre-engraft-
ment granulocytopenia. In the following days, the
clinical condition and CT-scan imaging deterior-
ated, with the development of new pulmonary
lesions and pleural and pericardial exudates,
associated with an increase in s-GM-a. The
pleural effusion was aspirated and yielded a
strain of Aspergillus fumigatus. Liposomal amph-
otericin B was increased to 5 mg ⁄ kg ⁄day, but the
clinical condition continued to deteriorate, and
voriconazole was substituted for liposomal
amphotericin B. After voriconazole therapy for 2
weeks, following further deterioration in the
clinical condition, coupled with an increase in
the number and extent of the pulmonary lesions
and detection of very high levels of s-GM-a,
caspofungin was added. After some days, the s-
GM-a levels decreased sharply and the clinical
condition improved. Unfortunately, 1 week later,
following a further reduction in the s-GM-a level,
the patient developed septic shock and died.
Blood cultures yielded a strain of oxacillin-resist-
ant coagulase-negative Staphylococcus. An aut-
opsy was not performed because of parental
refusal.
It has been demonstrated that a combination of
caspofungin with liposomal amphotericin B rep-
resents an effective option for the treatment of
immunocompromised adults with severe pul-
monary mycoses that do not respond to single-
agent therapy [6]. Of the three children described
in the present report, two had documented severe
pulmonary mycoses, and the third was a prob-
able case. None of these patients responded to
single-drug antifungal therapy with either
liposomal amphotericin B or voriconazole. In
the first case, addition of caspofungin produced
a rapid improvement in the patient’s clinical
condition. The second patient also showed clear
clinical improvement following combination ther-
apy. The third patient had the worst clinical
history, and the efficacy of combination therapy
could be evaluated only on the basis of clinical
improvement associated with a reduction in the
s-GM-a level (considered to be a reliable prog-
nostic factor [8]). All three patients tolerated the
combination therapy well; the mild toxicity
observed in the second patient could have been
multifactorial (resulting from the combination of
cyclosporin, liposomal amphotericin B and ca-
spofungin) and was reversed by substituting
tacrolimus for cyclosporin. Therefore, although
limited, these observations encourage the belief
that use of caspofungin in combination with other
antifungal drugs may be a useful therapeutic
option for immunocompromised children with
refractory invasive mycoses. These data, com-
bined with those from adults, suggest the need
for further trials of caspofungin in combination
with other antifungal drugs for the treatment of
life-threatening fungal infections that do not
respond to standard therapy.
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A B S T R A C T
Anti-Helicobacter pylori IgG serum levels were
measured in 31 young male bronchiectasis
patients without gastrointestinal symptoms, and
56 healthy males. The possible presence of
H. pylori was also investigated by rapid urease
tests, culture and histopathological examination
of protected catheter brush and biopsy specimens
from the bronchiectatic site. No serological,
microbiological or histological evidence of
H. pylori infection was found in the bronchiectasis
patient group. H. pylori did not appear to be an
agent of infection or chronic colonisation in
bronchiectasis, and may not have a significant
role in the progression of this disease.
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It has been suggested that Helicobacter pylori has a
role in the development of gastritis [1], peptic ulcer
[1] and gastric lymphoma [2], and that it is also
associated with ischaemic heart disease [3], cere-
brovascular disease [3] and rosacea [4,5]. The
presence of H. pylori at sites other than gastric
mucosa has not been shown clearly in humans, but
strains of H. pylori isolated from saliva and dental
plaque are generally identical to those isolated
from the stomach [6,7], and it is possible that
H. pylori might be introduced into the lung via
aspiration of saliva and gastric contents. H. pylori
has been isolated from tracheal secretions [8], and
the possible relationship between bronchiectasis
and H. pylori has been investigated by serological
tests [9,10]. The aim of the present study was to
evaluate whether H. pylori exists in the lung or is a
cause of infection in patients with bronchiectasis.
Thirty-one male patients with bronchiectasis
and 56 healthy controls were enrolled. Patients
with a history of disease that could be associated
with H. pylori (e.g., gastritis, peptic ulcer, gastric
lymphoma, coronary artery disease), other lung
diseases or antibiotic use during the previous
month were excluded. The study was approved
by the Hospital Research Committee, and
informed consent was obtained from all subjects.
Bronchiectasis was diagnosed by thorax high-
resolution computerised tomography (Somatom
DR-H; Siemens, Munich, Germany). Age and
smoking history (i.e., smoker or non-smoker)
were recorded, but other demographics were
not recorded since all subjects were white male
soldiers and shared virtually the same living
conditions. Spirometric functions, such as forced
vital capacity, forced expiratory volume in 1 s, as
a percentage of the predicted value (Spiromate
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